Výsledky vyhledávání - "Spenser S. Johnson"

Akademický článek

Auranofin inhibition of thioredoxin reductase sensitizes lung neuroendocrine tumor cells (NETs) and small cell lung cancer (SCLC) cells to sorafenib as well as inhibiting SCLC xenograft growth

Autor: Spenser S. Johnson, Dijie Liu, Jordan T. Ewald, Claudia Robles-Planells, Casey Pulliam, Keegan A. Christensen, Khaliunaa Bayanbold, Brian R. Wels, Shane R. Solst, M. Sue O’Dorisio, Yusuf Menda, Douglas R. Spitz, Melissa A. Fath

Publikováno v: Cancer Biology & Therapy, Vol 25, Iss 1 (2024)

Thioredoxin Reductase (TrxR) functions to recycle thioredoxin (Trx) during hydroperoxide metabolism mediated by peroxiredoxins and is currently being targeted using the FDA-approved anti-rheumatic drug, auranofin (AF), to selectively sensitize cancer

Externí odkaz: https://doaj.org/article/c5a3742216384e1498585e82c931ad1b

Zobrazit plný text záznamu

Auranofin Inhibition of Thioredoxin Reductase in a Preclinical Model of Small Cell Lung Cancer

Autor: Spenser S. Johnson, Dijie Liu, Jordan T. Ewald, Claudia Robles-Planells, Khaliunaa Bayanbold, Brian R. Wels, Shane R. Solst, M. Sue O’Dorisio, Bryan G. Allen, Yusuf Menda, Douglas R. Spitz, Melissa A. Fath

Publikováno v: bioRxiv

Thioredoxin Reductase (TrxR) is a key enzyme in reactive oxygen species (ROS) detoxification and in redox regulation. Because cancer cells produce increased steady-state levels of ROS (i.e., superoxide and hydrogen peroxide), TrxR is viable target in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9db2b29a43eee17c37e62aa5bb71f97e
https://doi.org/10.1101/2023.05.07.539772

Zobrazit plný text záznamu

Abstract 5034: Targeting CXCR4 and thioredoxin reductase in high grade neuroendocrine tumors and neuroendocrine carcinomas

Autor: Melissa A. Fath, Dijie Liu, Claudia Robles-Planells, Jordan T. Ewald, Keegan A. Christensen, Spenser S. Johnson, Stephen A. Graves, Douglas R. Spitz, Yusuf Menda, M. Sue O’Dorisio

Publikováno v: Cancer Research. 83:5034-5034

Introduction/Background: Atypical lung carcinoids and lung neuroendocrine carcinomas (NECs) are currently incurable. Most of these cancers express the C-X-C chemokine receptor 4 (CXCR4), making CXCR4 an attractive target for cancer diagnosis and trea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::37c03d943a083aa4b2628c80b04602bd
https://doi.org/10.1158/1538-7445.am2023-5034

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání